KR20210146934A - 천식 치료를 위한 리포칼린 뮤테인 - Google Patents

천식 치료를 위한 리포칼린 뮤테인 Download PDF

Info

Publication number
KR20210146934A
KR20210146934A KR1020217031533A KR20217031533A KR20210146934A KR 20210146934 A KR20210146934 A KR 20210146934A KR 1020217031533 A KR1020217031533 A KR 1020217031533A KR 20217031533 A KR20217031533 A KR 20217031533A KR 20210146934 A KR20210146934 A KR 20210146934A
Authority
KR
South Korea
Prior art keywords
fragment
variant
lipocalin mutein
subject
lipocalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217031533A
Other languages
English (en)
Korean (ko)
Inventor
레나 테레즈 악셀손
데이비드 로버트 클로즈
필립 가디너
아울리키 잉거가드 알렉산드라 자우히아니넨
예카테리나 파르달리
메리 피츠제럴드
가브리엘 매치너
잉마르 브룬스
건넬 마리타 올슨
Original Assignee
아스트라제네카 에이비이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 에이비이 filed Critical 아스트라제네카 에이비이
Publication of KR20210146934A publication Critical patent/KR20210146934A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
KR1020217031533A 2019-03-29 2020-03-25 천식 치료를 위한 리포칼린 뮤테인 Ceased KR20210146934A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962826791P 2019-03-29 2019-03-29
US62/826,791 2019-03-29
US201962845774P 2019-05-09 2019-05-09
US62/845,774 2019-05-09
US201962906443P 2019-09-26 2019-09-26
US62/906,443 2019-09-26
PCT/EP2020/058360 WO2020200960A1 (en) 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma

Publications (1)

Publication Number Publication Date
KR20210146934A true KR20210146934A (ko) 2021-12-06

Family

ID=70008540

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031533A Ceased KR20210146934A (ko) 2019-03-29 2020-03-25 천식 치료를 위한 리포칼린 뮤테인

Country Status (11)

Country Link
US (1) US20220193191A1 (https=)
EP (1) EP3946415A1 (https=)
JP (1) JP2022526524A (https=)
KR (1) KR20210146934A (https=)
CN (1) CN113613669A (https=)
AU (1) AU2020252050A1 (https=)
CA (1) CA3133422A1 (https=)
IL (1) IL286756A (https=)
MA (1) MA55490A (https=)
SG (1) SG11202109839YA (https=)
WO (1) WO2020200960A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
KR20230121785A (ko) 2020-12-18 2023-08-21 아스트라제네카 에이비이 천식 치료용 리포칼린 뮤테인 건조 분말 제형
WO2023143351A1 (zh) 2022-01-29 2023-08-03 上海盛迪医药有限公司 糖皮质激素的药物偶联物
CN114780621B (zh) * 2022-06-23 2022-10-04 中铁电气化勘测设计研究院有限公司 一种轨道交通接触网缺陷检索方法
WO2025026216A1 (zh) 2023-07-28 2025-02-06 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
RU2569745C2 (ru) * 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
ES2710384T3 (es) * 2011-12-13 2019-04-24 Pieris Pharmaceuticals Gmbh Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores

Also Published As

Publication number Publication date
EP3946415A1 (en) 2022-02-09
AU2020252050A1 (en) 2021-11-11
IL286756A (en) 2021-10-31
JP2022526524A (ja) 2022-05-25
WO2020200960A1 (en) 2020-10-08
SG11202109839YA (en) 2021-10-28
CN113613669A (zh) 2021-11-05
US20220193191A1 (en) 2022-06-23
MA55490A (fr) 2022-02-09
CA3133422A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
KR20210146934A (ko) 천식 치료를 위한 리포칼린 뮤테인
EP2627673B1 (en) Therapies for improving pulmonary function
Hodsman et al. A phase 1, randomized, placebo‐controlled, dose‐escalation study of an anti‐IL‐13 monoclonal antibody in healthy subjects and mild asthmatics
US8410049B2 (en) Methods and kits for preventing hypoglycemia
Mastrandrea et al. Clinical evaluation of inhaled insulin
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
JP6758196B2 (ja) Ｃｏｐｄの治療におけるフルチカゾンフランカルボン酸エステル
CA3100834A1 (en) Formulations and methods for the prevention of opioid overdose
Phipps et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
TW202241490A (zh) 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
KR20130110225A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법
US20100063251A1 (en) Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
Mishra et al. Intratracheal interleukin-13 induces eosinophilic esophagitis (EE)
Petraitytė Utilization and costs of drugs for asthma and chronic obstructive pulmonary disease treatment in Lithuania on 2006-2009 year
Elsner et al. CRIC3, a chemokine receptor inactivator as a novel approach in the treatment of allergic diseases
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function
KR20080093016A (ko) 인터페론을 사용하여 폐질환을 치료하는 방법
HK1240824B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1240824A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601